Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for BMY
63.70
-0.48 (-0.75%)
After Hours: 63.70 0.00 (0.00%)
Oct 18, 4:09PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 63.55 - 64.70
52 week 46.01 - 66.10
Open 64.25
Vol / Avg. 5.60M/5.84M
Mkt cap 104.46B
P/E 23.21
Div/yield 0.39/2.45
EPS 2.74
Shares 1.64B
Beta 1.19
Inst. own 70%
Oct 26, 2017
Q3 2017 Bristol-Myers Squibb Co Earnings Call - 10:30AM EDT - Add to calendar
Oct 26, 2017
Q3 2017 Bristol-Myers Squibb Co Earnings Release - 9:30AM EDT - Add to calendar
Sep 28, 2017
Bristol-Myers Squibb Co at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology - Webcast
Sep 11, 2017
Bristol-Myers Squibb Co at Morgan Stanley Healthcare Conference - Webcast
Jul 27, 2017
Q2 2017 Bristol-Myers Squibb Co Earnings Call - Webcast
Jul 27, 2017
Q2 2017 Bristol-Myers Squibb Co Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 17.92% 23.20%
Operating margin 25.95% 30.61%
EBITD margin - 30.93%
Return on average assets 11.15% 13.77%
Return on average equity 25.24% 29.28%
Employees 25,000 -
CDP Score - A-

Address

345 PARK AVE
NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Officers and directors

Giovanni Caforio M.D. Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer and Executive Vice President - Global Business Operations
Age: 57
Bio & Compensation  - Reuters
Louis S. Schmukler President - Global Manufacturing and Supply
Age: 61
Bio & Compensation  - Reuters
Ann Powell Judge Chief Human Resource Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Thomas J. Lynch Jr., M.D., Ph.D. Executive Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Murdo Gordon Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Paul von Autenried Senior Vice President, Chief Information Officer
Age: 55
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 56
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance